Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, CB2 0XY, Cambridge, UK.
Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Hills Road, CB2 0QQ, Cambridge, UK.
Neurotherapeutics. 2020 Oct;17(4):1539-1562. doi: 10.1007/s13311-020-00940-4. Epub 2020 Oct 30.
Parkinson's disease (PD) is a neurodegenerative disorder that carries large health and socioeconomic burdens. Current therapies for PD are ultimately inadequate, both in terms of symptom control and in modification of disease progression. Deep brain stimulation and infusion therapies are the current mainstay for treatment of motor complications of advanced disease, but these have very significant drawbacks and offer no element of disease modification. In fact, there are currently no agents that are established to modify the course of the disease in clinical use for PD. Gene and cell therapies for PD are now being trialled in the clinic. These treatments are diverse and may have a range of niches in the management of PD. They hold great promise for improved treatment of symptoms as well as possibly slowing progression of the disease in the right patient group. Here, we review the current state of the art for these therapies and look to future strategies in this fast-moving field.
帕金森病(PD)是一种神经退行性疾病,给患者带来了巨大的健康和社会经济负担。目前的 PD 治疗方法在控制症状和减缓疾病进展方面都不尽如人意。深部脑刺激和输注疗法是治疗晚期疾病运动并发症的当前主要方法,但这些方法存在非常显著的缺点,并且不能改变疾病的进程。事实上,目前在临床上没有能够改变 PD 疾病进程的药物。用于 PD 的基因和细胞疗法目前正在临床试验中进行。这些治疗方法多种多样,在 PD 的治疗中可能有多种用途。它们为改善症状以及在适当的患者群体中可能减缓疾病进展提供了很大的希望。在这里,我们回顾了这些疗法的最新进展,并展望了这一快速发展领域的未来策略。